Navigation Links
Max Neeman Develops Innovative Approach for Rare Disease Studies
Date:3/1/2011

RESEARCH TRIANGLE PARK, N.C., March 1, 2011 /PRNewswire/ -- Max Neeman International has established a team of experts specialized in carrying out rare disease trials in response to sponsor demand. The team has the required expertise to develop innovative approaches to optimize complex study design.  Often strict inclusion/exclusion criteria and data analysis for rare disease studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.

(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO)

Max Neeman is a leading CRO in India that has a focus on Rare Disease Studies, in addition to other indications.  Patient enrollment for rare disease, complex global and multi-centric trials is challenging because potential subjects are fewer in number and widely dispersed.  India has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment supported by the country's diverse gene pool and vast population of 1.3B.

Rare diseases are frequently life-threatening or chronically debilitating. However, drug development for these conditions has been limited by relative unavailability of subjects for clinical trials, as well as the high cost of investing in a novel pharmaceutical agent with poor market potential.  

Max Neeman International conducts India-based clinical research services for clients across the globe delivering quality results and exceptional customer service at a lower cost resulting in high client satisfaction.

About Max Neeman International

Max Neeman International is one of the leading and largest CROs in India and the clinical research arm of healthcare conglomerate, Max India.  Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company has 6 regional offices and 175 sites across 31 cities. Contact Donald Swankie, Vice President USA via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  www.neeman-medical.com

About Max Healthcare

Also part of the Max India group, Max Healthcare is one of a leading chain of hospitals in India.  State of the art infrastructure, India/Europe/USA trained physicians, and most advanced technologies make it one of the best hospitals in the country. www.maxhealthcare.in


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
4. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
5. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
6. Max Neeman International ISO 27001:2005 Certified for Information Security Management Systems
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Nventa Develops Proprietary Vaccine Adjuvant
9. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
10. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
11. Binghamton Research Group Develops New Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Report provides a basic overview of the industry ... which the surgical mesh report explores into the ... Complete report on Surgical Mesh market spread ... 98 tables and figures is available at ...
(Date:5/2/2016)... Leading Economies with Fastest Real GDP Annual Percentage Change, 2015  ... 7.3, , Source: IMF and TechSci Research   ... Brazil , Russia , India , ... the fastest GDP growth during the first decade of the 21 st ... Brazil and Russia , along with policy ...
(Date:5/2/2016)... , May 2, 2016  Celsion Corporation (NASDAQ: ... company, today announced data from the first cohort ... clinical trial (the OVATION Study) combining GEN-1, the ... for the treatment of newly-diagnosed patients with advanced ... by interval debulking surgery.  In the first three ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... California health startup Pegara announced ... helps people assess their risk of developing Alzheimer’s disease. Using a questionnaire based ... “Risk Reduction Score™” that summarizes how their lifestyle choices may affect their chances ...
(Date:5/3/2016)... Yorba Linda, CA (PRWEB) , ... May 03, ... ... exponential enrichment) is a process that selects DNA or RNA from a random ... ligands—called aptamers—could potentially be used as drugs or diagnostic agents. SELEX selection is ...
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking ... her with one on her shoulder and one on her arm. But she got ... of years of mitral valve prolapse. , The valves of the heart wouldn’t close ...
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a leader in ... a three hospital system in South Carolina, to provide its secure mobile communication ... that enhances communication, drives workflow efficiencies and improves provider and patient satisfaction,” said ...
(Date:5/3/2016)... , ... May 03, 2016 , ... Each year, about ... cause of death across the United States and account for one death every four ... impairments or are permanently disabled. HCR ManorCare is launching a video series called “Your ...
Breaking Medicine News(10 mins):